NEW DELHI – India cleared two hepatitis C generics drugs within a week, setting the stage for fierce competition between the two Hyderabad-based companies and, possibly, lower prices for much needed drugs.
NEW DELHI – India cleared two hepatitis C generics drugs within a week, setting the stage for fierce competition between the two Hyderabad-based companies and, possibly, lower prices for much needed drugs.
NEW DELHI – Indian generics drugmaker Cipla Ltd. said it will explore all legal options available after an Indian court's recent ruling that the firm infringed the patent rights of Swiss drug major Roche AG regarding lung cancer drug erlotinib.
NEW DELHI – Indian generics drugmaker Cipla Ltd. said it will explore all legal options available after an Indian court's recent ruling that the firm infringed the patent rights of Swiss drug major Roche AG regarding lung cancer drug erlotinib.
NEW DELHI – There has been mixed reaction – by and large welcoming – among India's pharmaceutical and biotechnology industry to a proposal by the Indian government to simplify corporate tax laws and end a "sunset" clause for companies that receive tax benefits as part of setting up in special economic zones (SEZ).
NEW DELHI – There has been mixed reaction – by and large welcoming – among India's pharmaceutical and biotechnology industry to a proposal by the Indian government to simplify corporate tax laws and end a "sunset" clause for companies that receive tax benefits as part of setting up in special economic zones (SEZ).
NEW DELHI – India's Central Drugs Standards Control Organisation (CDSCO) issued a slew of notifications in November aiming to speed up clinical trial approvals following concerns from companies that many regulatory requirements are duplicated and often tedious.
